Traitements médicaux des tumeurs ovariennes présumées bénignes

review OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by gemini-2.5-flash-lite, 2026-06-10

This paper reviews the medical treatments for presumed benign ovarian tumors.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Medical treatment of functional cysts and endometriomas, and the risk of developing functional ovarian cysts in different therapeutic situations are assessed. The available literature regarding the treatment of functional cysts is limited both by the number of studies and the variability of criteria used to define cysts. There is no evidence to support any efficiency of a medical treatment (LE1). However, oral contraceptive use reduces the risk of development of functional cysts (LE2). Using a second generation combination is recommended as a first-line option in order to reduce thromboembolic risk (LE1). Tamoxifen is significantly associated with an increased risk of developing unilocular cysts before menopause (LE2). For endometriomas, GnRH-agonists are not recommended before cystectomy in order to facilitate surgery (grade C) or to prevent recurrence (grade B). After surgery of endometriomas, the use of an intrauterine device with levonorgestrel or oral contraceptives significantly reduces the volume of the cyst in case of recurrence (LE3); oral contraceptives reduce the recurrence rate of endometriomas (LE2); the use of a low-dose oral contraceptive decreases the frequency and severity of long-term dysmenorrhea (LE1).

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Ovarian Cysts Ovarian Neoplasms Administration, Oral Contraceptives, Oral Contraceptives, Oral Diagnosis, Differential Drug Combinations Endometriosis Endometriosis Endometriosis Ethinyl Estradiol Ethinyl Estradiol Female Humans Norpregnenes Norpregnenes Ovarian Cysts Ovarian Cysts Ovarian Cysts Ovarian Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (5)

Source provenance

europepmc
last seen: 2026-08-30T09:23:35.175841+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:47.062786+00:00
unpaywall
last seen: 2026-09-03T06:36:50.994332+00:00
License: CC0 · commercial use OK